In a key study published on December 6, 2022, in Nature Communications Medicine, Ewart et al. introduced a paradigm-shifting solution to the inefficient drug discovery process (1). It entails the incorporation of Liver-Chip platforms as refinement tools within the preclinical assessment and lead optimization stages. This work first appeared in bioRxiv and is now entitled “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology.”

Read Full Article Below: